Smith Group Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Smith Group Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,060	Closed	-$39K	–	472
2015 Q3	$39K	Buy	4,060 +530	+15%	+$4.86K	﹤0.01%	292
2015 Q2	$36K	Buy	+3,530	New	+$30.1K	﹤0.01%	290

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Smith Group Asset Management's AKBA Position: Q4 2015 in Review

Smith Group Asset Management sold out of Akebia Therapeutics (AKBA) in Q4 2015, closing a stake of 4,060 shares — an estimated $39K sold.

Smith Group Asset Management first reported a position in AKBA in Q2 2015 and held it in 2 quarters. The position peaked at $39K in Q3 2015. 90 funds tracked by Wall St. Rank hold AKBA as of Q4 2015.

Smith Group Asset Management reported no remaining Akebia Therapeutics position as of Q4 2015 after selling out during the quarter.
Smith Group Asset Management sold 4,060 Akebia Therapeutics shares in Q4 2015, an estimated $39K.
Smith Group Asset Management first reported a position in Akebia Therapeutics in Q2 2015 and held it in 2 quarters.
Smith Group Asset Management's Akebia Therapeutics position peaked at $39K in Q3 2015.
90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.